At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Pomalidomide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Multicenter Study of Pomalidomide Monotherapy in HIV-Positive Individuals With Kaposi Sarcoma (KS) in Sub-Saharan Africa (SSA)
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Pomalidomide for Human Immunodeficiency Virus 1 Positive and Skin Kaposi Sarcoma. Completed, enrolled 26 participants across 3 sites in 3 countries.
Detailed Summary
This phase II clinical trial studies the side effects of pomalidomide and how well it works in treating patients with Kaposi sarcoma and human immunodeficiency virus (HIV) infection. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop tumor cells from growing and it may also block the growth of new blood vessels necessary for tumor growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesKenya, Malawi, Uganda
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartApr 2021
Primary CompletionNov 2024
Study CompletionApr 2025
TodayJul 2026
First PostedJul 26, 2018
Enrollment StartApr 26, 2021
Primary CompletionNov 29, 2024
Study CompletionApr 10, 2025
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 7.9 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Pomalidomidedrug
Given PO